Treatment with the dopamine receptor D2 (DRD2) agonist bromocriptine improves metabolic features in obese patients with type 2 diabetes by a still unknown mechanism. In the present study, we investigated the acute effect of bromocriptine and its underlying mechanism(s) on insulin secretion both in vivo and in vitro. For this purpose, C57Bl6/J mice were subjected to an intraperitoneal glucose to...

The aim of this study was to investigate the effects of magnesium as a N-Methyl–D-Aspartate (NMDA) receptor Antagnist and bromocriptine as a dopamine receptor agonist on morphine dependence and withdrawal symptoms. In the present study different groups of mice were received morphine (50 mg/kg, i.p.) for four days and on fourth day 1.5 hour after the last morphine administration they received di...

Thirty-one patients with Parkinson's disease were treated with the ergot alkaloid bromocriptine, a drug which stimulates dopamine receptors. Bromocriptine had a slight therapeutic effect in patients on no other treatment and an additional effect in patients on levodopa. The mean optimum dosage of bromocriptine, established over a 12 week period, was 26 mg daily. In 20 patients bromocriptine was...

To ascertain the mechanisms of bromocriptine in lowering serum prolactin (PRL) levels and reducing the cell size of human prolactinomas, stereological analysis at electron microscope level was performed on six adenomas treated with bromocriptine (10 mg/day for 2 weeks) and four untreated adenomas. The bromocriptine treatment significantly decreased all the major organelles involved in PRL synth...

The American Journal of Occupational Therapy Survivors of brain injuries often experience multiple cognitive, behaVioral, and motor deficits that they must learn to remediate or compensate for to become functional in daily self-care tasks as well as mobility tasks, Executive dysfunction is a generalized term used to indicate the ability to integrate higher level cognitive skills, Executive dysf...

Objectives: to compare the clinical effectiveness, side effects and tolerability of rectal versus vaginal bromocreptine/pluronic F-127suppositories as compared to oral bromocriptine tablets for treating pathologic hyperprolactinemia. Design: An active comparator randomized study. Setting: A pharmaceutical phase at the department of Pharmaceutics, Faculty of Pharmacy, and a clinical phase at the...

A 45-year-old woman presented with worsening of migraine without aura. Laboratory test revealed hyperprolactinemia, but brain magnetic resonance imaging was normal. She had no known etiologies hyperprolactinemia. Headache improved together normalization serum prolactin level after administration bromocriptine. However, withdrawal bromocriptine caused elevation and headache. repeated similar pat...

Problem statement: The literature is reviewed and supports a strong anecdotal relationship between bromocriptine use and psychosis. It is well known that any interference with brain amino acid levels is likely to lead to disorder. Our previous research has shown that bromocriptine produced significant changes in the heart and kidneys amino acid contents. It has been confirmed that the brain ami...

Objective: To measure and to evaluate the effect of bromocriptine on the concentration of uric acid in infertile women with hyperprolactinema. Methods: Sixty infertile women, who had serum prolactin concentration at least twice the upper limit of normal values participated in this study. Serum prolactin and uric acid concentrations were measured before and after giving bromocriptine 2.5 mg oral...

The progress of 50 previously untreated patients with idiopathic Parkinson's disease taking maximum tolerated doses of bromocriptine is described. Twenty-eight showed sustained benefit, defined as a 25% improvement in disability scores for at least 1 year, and in five this improvement persisted for longer than 5 years. However, there was a tendency for deterioration to occur after about 2 years...